Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902191 | 1.00 | CTSK (0.51) | CTSKCACNA1BMAPK1KMT2ACYP2C19 | |
| SCHEMBL5582055 | 0.92 | CACNA1B (0.47) | CTSKCACNA1BKMT2ACYP2C19 | |
| SCHEMBL5582054 | 0.92 | CACNA1B (0.47) | CTSKCACNA1BKMT2ACYP2C19 | |
| SCHEMBL5099152 | 0.91 | MMP2 (0.48) | CTSKCACNA1BKMT2A | |
| SCHEMBL7562941 | 0.91 | MMP2 (0.48) | CTSKCACNA1BKMT2A | |
| SCHEMBL5099149 | 0.91 | MMP2 (0.48) | CTSKCACNA1BKMT2A | |
| SCHEMBL5105702 | 0.91 | CACNA1B (0.46) | CTSKCACNA1B | |
| SCHEMBL5105698 | 0.91 | CACNA1B (0.46) | CTSKCACNA1B | |
| SCHEMBL6635523 | 0.90 | CACNA1B (0.45) | CTSKCACNA1B | |
| SCHEMBL5105827 | 0.90 | CACNA1B (0.45) | CTSKCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | CTSK 47/4885CACNA1B 3902/4885MAPK1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.